Fed. Circ. Upholds Invalidity Of J&J Concerta Patent

Law360, New York (April 28, 2010, 5:32 PM EDT) -- A federal appeals court has affirmed the invalidity of Johnson & Johnson's patent for attention deficit hyperactivity disorder treatment Concerta, thwarting the health care company's attempt to block Andrx Corp. from launching a generic version.

The U.S. Court of Appeals for the Federal Circuit ruled Monday that the patent was invalid for lack of enablement, affirming the U.S. District Court for the District of Delaware's March 2009 opinion in favor of Andrx.

U.S. Patent Number 6,919,373 claims methods for treating ADHD through a methylphenidate drug dosage...
To view the full article, register now.